|
1
|
Sandhu DS, Baichoo E and Roberts LR:
Fibroblast growth factor signaling in liver carcinogenesis.
Hepatology. 59:1166–1173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yun YR, Won JE, Jeon E, Lee S, Kang W, Jo
H, Jang JH, Shin US and Kim HW: Fibroblast growth factors: Biology,
function, and application for tissue regeneration. J Tissue Eng.
2010:2181422010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Linscott ML and Chung WC: Fibroblast
growth factor 8 expression in GT1-7 GnRH-secreting neurons is
androgen-independent, but can be upregulated by the inhibition of
DNA methyltransferases. Front Cell Dev Biol. 4:342016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen N, Ma J, Zhao Y, Wu M, Yang H, Gong
W, Chao J and Li X: Expression of functional recombinant human
fibroblast growth factor 8b and its protective effects on
MPP+-lesioned PC12 cells. Appl Microbiol Biotechnol.
100:625–635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu R, Huang S, Lei Y, Zhang T, Wang K,
Liu B, Nice EC, Xiang R, Xie K, Li J, et al: FGF8 promotes
colorectal cancer growth and metastasis by activating YAP1.
Oncotarget. 6:935–952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhong C, Saribekyan G, Liao CP, Cohen MB
and Roy-Burman P: Cooperation between FGF8b overexpression and PTEN
deficiency in prostate tumorigenesis. Cancer Res. 66:2188–2194.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dorkin TJ, Robinson MC, Marsh C, Bjartell
A, Neal DE and Leung HY: FGF8 over-expression in prostate cancer is
associated with decreased patient survival and persists in androgen
independent disease. Oncogene. 18:2755–2761. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
10
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Pasolli HA and Fuchs E:
Yes-associated protein (YAP) transcriptional coactivator functions
in balancing growth and differentiation in skin. Proc Natl Acad Sci
USA. 108:2270–2275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nguyen Q, Anders RA, Alpini G and Bai H:
Yes-associated protein in the liver: Regulation of hepatic
development, repair, cell fate determination and tumorigenesis. Dig
Liver Dis. 47:826–835. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kowalik MA, Saliba C, Pibiri M, Perra A,
Ledda-Columbano GM, Sarotto I, Ghiso E, Giordano S and Columbano A:
Yes-associated protein regulation of adaptive liver enlargement and
HCC development in mice. Hepatology. 53:2086–2096. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosenbluh J, Nijhawan D, Cox AG, Li X,
Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et
al: β-catenin-driven cancers require a YAP1 transcriptional complex
for survival and tumorigenesis. Cell. 151:1457–1473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kapoor A, Yao W, Ying H, Hua S, Liewen A,
Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, et al: Yap1 activation
enables bypass of oncogenic Kras addiction in pancreatic cancer.
Cell. 158:185–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lorenzetto E, Brenca M, Boeri M, Verri C,
Piccinin E, Gasparini P, Facchinetti F, Rossi S, Salvatore G,
Massimino M, et al: YAP1 acts as oncogenic target of 11q22
amplification in multiple cancer subtypes. Oncotarget. 5:2608–2621.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Panvichian R, Tantiwetrueangdet A,
Sornmayura P and Leelaudomlipi S: Missense mutations in exons 18–24
of EGFR in HCC tissues. Biomed Res Int. 2015:1718452015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lanaya H, Natarajan A, Komposch K, Li L,
Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic
M, et al: EGFR has a tumour-promoting role in liver macrophages
during HCC formation. Nat Cell Biol. 16:972–981. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Badawy AA, El-Hindawi A, Hammam O, Moussa
M, Gabal S and Said N: Impact of epidermal growth factor receptor
and transforming growth factor-α on hepatitis C virus-induced
hepatocarcinogenesis. APMIS. 123:823–831. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thomas MB, Morris JS, Chadha R, Iwasaki M,
Kaur H, Lin E, Kaseb A, Glover K, Davila M and Abbruzzese J: Phase
II trial of the combination of bevacizumab and erlotinib in
patients who have advanced HCC. J Clin Oncol. 27:843–850. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yau T, Wong H, Chan P, Yao TJ, Pang R,
Cheung TT, Fan ST and Poon RT: Phase II study of bevacizumab and
erlotinib in the treatment of advanced HCC patients with
sorafenib-refractory disease. Invest New Drugs. 30:2384–2390. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Zong Y, Xu GZ and Xing K:
Erlotinib for advanced HCC. A systematic review of phase II/III
clinical trials. Saudi Med J. 37:1184–1190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llovet JM and Bruix J: Testing molecular
therapies in HCC: The need for randomized phase II trials. J Clin
Oncol. 27:833–835. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu HR, Park SC, Choi SJ, Lee JC, Kim YC,
Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, et al: Combined treatment
with silibinin and either sorafenib or gefitinib enhances their
growth-inhibiting effects in HCC cells. Clin Mol Hepatol. 21:49–59.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei Z, Doria C and Liu Y: Targeted
therapies in the treatment of advanced HCC. Clin Med Insights
Oncol. 7:87–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ezzoukhry Z, Louandre C, Trécherel E,
Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC and
Galmiche A: EGFR activation is a potential determinant of primary
resistance of HCC cells to sorafenib. Int J Cancer. 131:2961–2969.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu HC, Chen HJ, Chang YL, Liu CY, Shiau
CW, Cheng AL and Chen KF: Inhibition of CIP2A determines
erlotinib-induced apoptosis in HCC. Biochem Pharmacol. 85:356–366.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huether A, Höpfner M, Sutter AP, Schuppan
D and Scherübl H: Erlotinib induces cell cycle arrest and apoptosis
in hepatocellular cancer cells and enhances chemosensitivity
towards cytostatics. J Hepatol. 43:661–669. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao J, Kelnar K and Bader AG: In-depth
analysis shows synergy between erlotinib and miR-34a. PLoS One.
9:e891052014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song S, Honjo S, Jin J, Chang SS, Scott
AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et
al: The Hippo coactivator YAP1 mediates EGFR overexpression and
confers chemoresistance in esophageal cancer. Clin Cancer Res.
21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu X, Feng D, Liu D, Wang S, Yu X, Dai E,
Wang J, Wang L and Jiang W: Dissecting the origin of breast cancer
subtype stem cell and the potential mechanism of malignant
transformation. PLoS One. 11:e01650012016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song K, Wu J and Jiang C: Dysregulation of
signaling pathways and putative biomarkers in liver cancer stem
cells (Review). Oncol Rep. 29:3–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Di C and Zhao Y: Multiple drug resistance
due to resistance to stem cells and stem cell treatment progress in
cancer (Review). Exp Ther Med. 9:289–293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu
Y, Jin ZR, Li XQ, Liu QZ, Sun DX, et al: Cancer stem-like cell
properties are regulated by EGFR/AKT/β-catenin signaling and
preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
FEBS J. 280:2027–2041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu RX, Seto WK, Lai CL and Yuen MF:
Epidemiology of HCC in the Asia-Pacific Region. Gut Liver.
10:332–339. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gong XL and Qin SK: Progress in systemic
therapy of advanced HCC. World J Gastroenterol. 22:6582–6594. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Deng GL, Zeng S and Shen H: Chemotherapy
and target therapy for HCC: New advances and challenges. World J
Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brown KS: Chemotherapy and other systemic
therapies for HCC and liver metastases. Semin Intervent Radiol.
23:99–108. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pardee AD and Butterfield LH:
Immunotherapy of HCC: Unique challenges and clinical opportunities.
Oncoimmunology. 1:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
